AIM Rule 26

The following information is disclosed in accordance with Rule 26 of the AIM regulations.

Description of the business

The principal activity of the Group is the research, development and commercialisation of a range of cannabinoid prescription medicines, including Sativex®, to meet patient needs in a wide range of therapeutic indications.

Directors and committees

Click here for more information about the directors.

Click here for more information about the Remuneration Committee.

Click here for more information about the Audit Committee.

Click here for more information about the Nominations Committee.

Country of incorporation and main country of operation

GW Pharmaceuticals plc is incorporated in England (Registration number 4160917) which is also its main country of operation.

Current constitutional documents

Memorandum and Articles of Association

Securities in issue

Click here for more information about number of securities in issue and, insofar as the company is aware, the percentage of AIM securities not in public hands, together with the identity and percentage of significant shareholders.

Financial reports

Click here for access to the Company's Annual and Interim Reports.

Company announcements

Click here to access the Notice of Annual General Meeting, which will be on the 24th of March 2010.

Click here to access notifications made by the Company.

Admission documents

Click here to access the Company's Admission Document from June 2001

Please note this document was issued more than six years ago and is accordingly substantially out of date. For more accurate and up-to-date information, please refer to the latest Annual Report, recent announcements and other such information sources on the web.

Advisors

Click here for details of the Company's nominated advisers.

This section of the website was last updated to comply with Rule 26 on: 02 November 2009